Longitudinal analysis of serum chemokine levels in the course of HIV-1 infection

被引:51
作者
Polo, S
Veglia, F
Malnati, MS
Gobbi, C
Farci, P
Raiteri, R
Sinicco, A
Lusso, P
机构
[1] Ist Sci San Raffaele, DIBIT, Unit Human Virol, I-20132 Milan, Italy
[2] Ist Sci San Raffaele, DIBIT, Biostat Unit, I-20132 Milan, Italy
[3] Univ Cagliari, Dept Internal Med, Cagliari, Italy
[4] Univ Turin, Dept Med & Surg Sci, Infect Dis Sect, Turin, Italy
关键词
AIDS; disease progression; chemokines; RANTES; prognostic factors;
D O I
10.1097/00002030-199903110-00002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To investigate the correlation between the serum levels of the CC-chemokines RANTES, macrophage inflammatory protein (MIP)-1 alpha and MIP-1 beta, and the progression of HIV-1 disease. Design: Retrospective analysis of serial serum samples from HIV-1 seroconverters selected according to clinical outcome. Methods: Twenty-one patients, derived from a cohort recruited between 1985 and 1996 for a prospective study of the natural history of HIV infection, were analysed. All patients had at least one HIV-1-seronegative sample within 1 year prior to the first seropositive test acid were followed longitudinally throughout the course of HIV-1 infection (mean follow-up, 73.5 months). Nine were rapid progressors (RP; patients who developed AIDS within 60 months of antibody seroconversion), seven were slow progressors (SP; patients who developed AIDS after GO months), and five were long-term asymptomatic (LTA; patients with circulating CD4+ cells higher than 400 x 10(6)/l, no signs of HIV disease, no antiretroviral therapy for more than 96 months). A total of 339 serum samples was studied (mean, 16.1 per patient). The levels of RANTES, MIP-1 alpha and MIP-1 beta were measured by enzyme-linked immunosorbent assay and correlated with different immunological and clinical parameters. Results: Over the entire follow-up period, the geometric mean of serum RANTES was significantly higher in RP [68.6 ng/ml; 95% confidence interval (CI), 56.9-82.7] than in SP (23.7 ng/ml; 95% CI, 20.0-28.2; P < 0.001) and LTA (19.5 ng/ml; 95% CI, 15.5-24.5; P < 0.001). This difference was already significant during the early clinical stages, when patients had peripheral blood CD4+ cell counts still greater than 400 x 10(6)/l (P < 0.001). By contrast, the mean serum levels of MIP-1 alpha and MIP-1 beta did not differ significantly between the three study groups. Multivariate analysis using the Cox proportional hazard model demonstrated that the mean serum concentration of RANTES before the development of AIDS was independently associated with the time to AIDS (relative risk, 4.5; 95% CI, 1.1-18.2; P = 0.035). in patients with low versus high mean serum RANTES before the fall of CD4+ cells below 400 x 10(6)/l, the median AIDS-free time was 117.5 and 42.7 months, respectively (P = 0.037). Conclusion: These data suggest that an elevation of serum RANTES predicts a rapid progression of the disease since the early stages of HIV-1 infection. (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码:447 / 454
页数:8
相关论文
共 37 条
[1]  
[Anonymous], 1987, MORBIDITY MORTALITY, V36, P3
[2]   Circulating levels of RANTES in human immunodeficiency virus type 1 infection:: Effect of potent antiretroviral therapy [J].
Aukrust, P ;
Müller, F ;
Froland, SS .
JOURNAL OF INFECTIOUS DISEASES, 1998, 177 (04) :1091-1096
[3]  
BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97
[4]  
Berger EA, 1997, AIDS, V11, pS3
[5]   Change in circulating levels of the chemokines macrophage inflammatory proteins 1 alpha and 1 beta, RANTES, monocyte chemotactic protein-1 and interleukin-16 following treatment of severely immunodeficient HIV-infected individuals with indinavir [J].
Bisset, LR ;
Rothen, M ;
JollerJemelka, HI ;
Dubs, RW ;
Grob, PJ ;
Opravil, M .
AIDS, 1997, 11 (04) :485-491
[6]   IDENTIFICATION OF RANTES, MIP-1-ALPHA, AND MIP-1-BETA AS THE MAJOR HIV-SUPPRESSIVE FACTORS PRODUCED BY CD8(+) T-CELLS [J].
COCCHI, F ;
DEVICO, AL ;
GARZINODEMO, A ;
ARYA, SK ;
GALLO, RC ;
LUSSO, P .
SCIENCE, 1995, 270 (5243) :1811-1815
[7]   Change in coreceptor use correlates with disease progression in HIV-1-infected individuals [J].
Connor, RI ;
Sheridan, KE ;
Ceradini, D ;
Choe, S ;
Landau, NR .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (04) :621-628
[8]   HIV-1 protease inhibitors - A review for clinicians [J].
Deeks, SG ;
Smith, M ;
Holodniy, M ;
Kahn, JO .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (02) :145-153
[9]   HIV-1 entry into CD4(+) cells is mediated by the chemokine receptor CC-CKR-5 [J].
Dragic, T ;
Litwin, V ;
Allaway, GP ;
Martin, SR ;
Huang, YX ;
Nagashima, KA ;
Cayanan, C ;
Maddon, PJ ;
Koup, RA ;
Moore, JP ;
Paxton, WA .
NATURE, 1996, 381 (6584) :667-673
[10]   THE PROGNOSTIC VALUE OF CELLULAR AND SEROLOGIC MARKERS IN INFECTION WITH HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 [J].
FAHEY, JL ;
TAYLOR, JMG ;
DETELS, R ;
HOFMANN, B ;
MELMED, R ;
NISHANIAN, P ;
GIORGI, JV .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (03) :166-172